252 related articles for article (PubMed ID: 21909374)
21. Targeting the ubiquitin-proteasome pathway: an emerging concept in cancer therapy.
Frezza M; Schmitt S; Dou QP
Curr Top Med Chem; 2011 Dec; 11(23):2888-905. PubMed ID: 21824109
[TBL] [Abstract][Full Text] [Related]
22. [Ubiquitin-proteasome pathway as a target for therapeutic strategies].
Staszczak M
Postepy Biochem; 2017; 63(4):287-303. PubMed ID: 29374430
[TBL] [Abstract][Full Text] [Related]
23. Therapeutically targeting the SUMOylation, Ubiquitination and Proteasome pathways as a novel anticancer strategy.
Driscoll JJ; Dechowdhury R
Target Oncol; 2010 Dec; 5(4):281-9. PubMed ID: 21125340
[TBL] [Abstract][Full Text] [Related]
24. Combination of proteasome and HDAC inhibitors for uterine cervical cancer treatment.
Lin Z; Bazzaro M; Wang MC; Chan KC; Peng S; Roden RB
Clin Cancer Res; 2009 Jan; 15(2):570-7. PubMed ID: 19147762
[TBL] [Abstract][Full Text] [Related]
25. The roles of E6-AP and MDM2 in p53 regulation in human papillomavirus-positive cervical cancer cells.
Traidej M; Chen L; Yu D; Agrawal S; Chen J
Antisense Nucleic Acid Drug Dev; 2000 Feb; 10(1):17-27. PubMed ID: 10726657
[TBL] [Abstract][Full Text] [Related]
26. Critical role of lysine 123 in the ubiquitin-mediated degradation of MDA-7/IL-24.
Tian H; Li L; Zhang B; Di J; Chen F; Li H; Liu J; Pei D; Zheng J
J Interferon Cytokine Res; 2012 Dec; 32(12):575-82. PubMed ID: 23078624
[TBL] [Abstract][Full Text] [Related]
27. Chemically induced degradation of CK2 by proteolysis targeting chimeras based on a ubiquitin-proteasome pathway.
Chen H; Chen F; Liu N; Wang X; Gou S
Bioorg Chem; 2018 Dec; 81():536-544. PubMed ID: 30245235
[TBL] [Abstract][Full Text] [Related]
28. Betulinic acid selectively increases protein degradation and enhances prostate cancer-specific apoptosis: possible role for inhibition of deubiquitinase activity.
Reiner T; Parrondo R; de Las Pozas A; Palenzuela D; Perez-Stable C
PLoS One; 2013; 8(2):e56234. PubMed ID: 23424652
[TBL] [Abstract][Full Text] [Related]
29. Impairment of the ubiquitin-proteasome pathway by methyl N-(6-phenylsulfanyl-1H-benzimidazol-2-yl)carbamate leads to a potent cytotoxic effect in tumor cells: a novel antiproliferative agent with a potential therapeutic implication.
Dogra N; Mukhopadhyay T
J Biol Chem; 2012 Aug; 287(36):30625-40. PubMed ID: 22745125
[TBL] [Abstract][Full Text] [Related]
30. Proteolytic degradation of heat shock protein A2 occurs in response to oxidative stress in male germ cells of the mouse.
Bromfield EG; Aitken RJ; McLaughlin EA; Nixon B
Mol Hum Reprod; 2017 Feb; 23(2):91-105. PubMed ID: 27932549
[TBL] [Abstract][Full Text] [Related]
31. Identification of the ubiquitin-proteasome pathway in the regulation of the stability of eukaryotic elongation factor-2 kinase.
Arora S; Yang JM; Hait WN
Cancer Res; 2005 May; 65(9):3806-10. PubMed ID: 15867377
[TBL] [Abstract][Full Text] [Related]
32. TC-N19, a novel dual inhibitor of EGFR and cMET, efficiently overcomes EGFR-TKI resistance in non-small-cell lung cancer cells.
Wu DW; Chen TC; Huang HS; Lee H
Cell Death Dis; 2016 Jun; 7(6):e2290. PubMed ID: 27362807
[TBL] [Abstract][Full Text] [Related]
33. Proteasome inhibition mediates p53 reactivation and anti-cancer activity of 6-gingerol in cervical cancer cells.
Rastogi N; Duggal S; Singh SK; Porwal K; Srivastava VK; Maurya R; Bhatt ML; Mishra DP
Oncotarget; 2015 Dec; 6(41):43310-25. PubMed ID: 26621832
[TBL] [Abstract][Full Text] [Related]
34. Processing of autophagic protein LC3 by the 20S proteasome.
Gao Z; Gammoh N; Wong PM; Erdjument-Bromage H; Tempst P; Jiang X
Autophagy; 2010 Jan; 6(1):126-37. PubMed ID: 20061800
[TBL] [Abstract][Full Text] [Related]
35. Lipoic Acid Synergizes with Antineoplastic Drugs in Colorectal Cancer by Targeting p53 for Proteasomal Degradation.
Neitzel C; Seiwert N; Göder A; Diehl E; Weber C; Nagel G; Stroh S; Rasenberger B; Christmann M; Fahrer J
Cells; 2019 Jul; 8(8):. PubMed ID: 31366086
[TBL] [Abstract][Full Text] [Related]
36. The significance of ubiquitin proteasome pathway in cancer development.
Yerlikaya A; Yöntem M
Recent Pat Anticancer Drug Discov; 2013 Sep; 8(3):298-309. PubMed ID: 23061719
[TBL] [Abstract][Full Text] [Related]
37. A novel nickel complex works as a proteasomal deubiquitinase inhibitor for cancer therapy.
Zhao C; Chen X; Zang D; Lan X; Liao S; Yang C; Zhang P; Wu J; Li X; Liu N; Liao Y; Huang H; Shi X; Jiang L; Liu X; He Z; Dou QP; Wang X; Liu J
Oncogene; 2016 Nov; 35(45):5916-5927. PubMed ID: 27086925
[TBL] [Abstract][Full Text] [Related]
38. Histone deacetylase inhibitor, trichostatin A induces ubiquitin-dependent cyclin D1 degradation in MCF-7 breast cancer cells.
Alao JP; Stavropoulou AV; Lam EW; Coombes RC; Vigushin DM
Mol Cancer; 2006 Feb; 5():8. PubMed ID: 16504004
[TBL] [Abstract][Full Text] [Related]
39. BAG3 induction is required to mitigate proteotoxicity via selective autophagy following inhibition of constitutive protein degradation pathways.
Rapino F; Jung M; Fulda S
Oncogene; 2014 Mar; 33(13):1713-24. PubMed ID: 23644654
[TBL] [Abstract][Full Text] [Related]
40. Ubiquitin proteasome system stress underlies synergistic killing of ovarian cancer cells by bortezomib and a novel HDAC6 inhibitor.
Bazzaro M; Lin Z; Santillan A; Lee MK; Wang MC; Chan KC; Bristow RE; Mazitschek R; Bradner J; Roden RB
Clin Cancer Res; 2008 Nov; 14(22):7340-7. PubMed ID: 19010849
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
